N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea |
| カタログ番号GC33752 |
N-[(1R)-4-[(アミノイミノメチル)アミノ]-1-[[[(1R)-1-(4-ヒドロキシフェニル)エチル]アミノ]カルボニル]ブチル]-α-フェニルベンゼンアセトアミドは、全般性強直間代発作および部分発作の治療に。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 97627-24-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
N-[(1R)-4-[(Aminoiminomethyl)amino]-1-[[[(1R)-1-(4-hydroxyphenyl)ethyl]amino]carbonyl]butyl]-α-phenylbenzeneacetamide is an anticonvulsant agent with potential for the treatment of generalized tonic-clonic and partial seizures.
Compound shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound is selected for clinical trials[1].
[1]. Pavia MR, et al. N-Phenyl-N'-pyridinylureas as Anticonvulsant Agents. J. Med. Chem. 1990,33, 854-861
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *